Topic: Astrazeneca Group
SAN DIEGO (Reuters) - A new type of diabetes pill being developed by Bristol-Myers Squibb and AstraZeneca was effective in a two-year study but more bladder and breast cancers have been found in patients treated with the drug.In all studies so far ...
SAN DIEGO (Reuters) - A new type of diabetes pill being developed by Bristol-Myers Squibb and AstraZeneca was effective in a two-year study, but the companies said more bladder and breast cancers have been seen in patients treated with the drug.In an ...
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone. "We are pleased to see the results from this Phase ...
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin ...
AstraZeneca pays $198 million to settle US lawsuits over antipsychotic drugAstraZeneca PLC says it has paid around $198 million to settle U.S. lawsuits over its antipsychotic drug Seroquel.AstraZeneca said Monday it has paid out to around 17,500 claimants regarding allegations the drug ...
Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in ...
PRINCETON, N.J. & Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and ...
Bristol-Myers, partner AstraZeneca get EU approval for diabetes drug Onglyza, rival for MerckDrugmaker Bristol-Myers Squibb Co. said Monday that its new diabetes drug, Onglyza, has been approved for sale in the European Union's 27 countries.That means Onglyza will compete with Merck & ...
PRINCETON, N.J. and Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZAT (saxagliptin) 5 mg per day achieved the primary objective of ...
FDA clears potential blockbuster diabetes drug from drugmakers Bristol-Myers and AstraZenecaFederal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC.The Food and Drug Administration said it approved the companies' drug Onglyza to reduce ...
From Around the Web
Video Gallery
-
Penny Stoker - AstraZeneca Pharmaceuticals LP
Penny Stoker, vice presdient, global hr services at AstraZeneca Pharmaceuticals ...2009-04-07 -
AstraZeneca - Tanuj
Tanuj is a physician who combined his health information and ...2011-11-28 -
AstraZeneca - Melissa
Melissa is a Senior Scientist who is part of a ...2011-11-28
